Arrowhead Pharmaceuticals announced interim results from two Phase 1/2a clinical trials of ARO-INHBE and ARO-ALK7, their investigational RNA interference therapeutics for obesity.
Results showed significant reductions in visceral fat, total fat, and liver fat, with promising weight loss outcomes in obese patients with type 2 diabetes mellitus.
The company's approach, especially with ARO-INHBE in combination with tirzepatide, demonstrated substantial improvements in multiple key measures of body composition.
Substantial Weight Loss
ARO-INHBE in combination with tirzepatide achieved a significant weight loss of -9.4% at week 16 in obese patients with type 2 diabetes mellitus.
Visceral Fat Reduction
ARO-INHBE and ARO-ALK7 showcased remarkable reductions in visceral fat, total fat, and liver fat, offering potential therapeutic benefits for obesity patients.
Unique RNAi Therapeutic Approach
ARO-ALK7 is the first RNAi-therapeutic to show knockdown in humans of an adipocyte expressed gene, heralding a new era in obesity treatment strategies.
- The interim results demonstrate promising advancements in obesity care and metabolic disease treatment through targeted reduction of visceral fat and improved body composition measures.
- Arrowhead's approach of combining RNAi therapeutics with existing treatments shows potential for significant improvements in weight loss outcomes for patients with obesity and type 2 diabetes mellitus.
The interim clinical data presented by Arrowhead Pharmaceuticals underscores the potential of RNAi-based therapies in addressing the challenges of obesity and metabolic diseases. With significant reductions in visceral fat and weight loss outcomes, the company's approach shows promise for improved treatment options in the future.